260 related articles for article (PubMed ID: 38360860)
1. Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma.
Tang S; Wang Y; Luo R; Fang R; Liu Y; Xiang H; Ran P; Tong Y; Sun M; Tan S; Huang W; Huang J; Lv J; Xu N; Yao Z; Zhang Q; Xu Z; Yue X; Yu Z; Akesu S; Ding Y; Xu C; Lu W; Zhou Y; Hou Y; Ding C
Nat Commun; 2024 Feb; 15(1):1381. PubMed ID: 38360860
[TBL] [Abstract][Full Text] [Related]
2. The proteomic landscape of soft tissue sarcomas.
Burns J; Wilding CP; Krasny L; Zhu X; Chadha M; Tam YB; Ps H; Mahalingam AH; Lee ATJ; Arthur A; Guljar N; Perkins E; Pankova V; Jenks A; Djabatey V; Szecsei C; McCarthy F; Ragulan C; Milighetti M; Roumeliotis TI; Crosier S; Finetti M; Choudhary JS; Judson I; Fisher C; Schuster EF; Sadanandam A; Chen TW; Williamson D; Thway K; Jones RL; Cheang MCU; Huang PH
Nat Commun; 2023 Jun; 14(1):3834. PubMed ID: 37386008
[TBL] [Abstract][Full Text] [Related]
3. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas.
Suehara Y; Kondo T; Fujii K; Hasegawa T; Kawai A; Seki K; Beppu Y; Nishimura T; Kurosawa H; Hirohashi S
Proteomics; 2006 Aug; 6(15):4402-9. PubMed ID: 16807943
[TBL] [Abstract][Full Text] [Related]
4. Current molecular and therapeutic advances in liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, and angiosarcoma.
Tanriverdi O; Yildiz A
J Oncol Pharm Pract; 2022 Apr; 28(3):635-645. PubMed ID: 35043739
[TBL] [Abstract][Full Text] [Related]
5. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
;
Cell; 2017 Nov; 171(4):950-965.e28. PubMed ID: 29100075
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Kim C; Kim EK; Jung H; Chon HJ; Han JW; Shin KH; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim SH; Kim HS
BMC Cancer; 2016 Jul; 16():434. PubMed ID: 27393385
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of soft tissue sarcoma.
Suehara Y
Int J Clin Oncol; 2011 Apr; 16(2):92-100. PubMed ID: 21384281
[TBL] [Abstract][Full Text] [Related]
9. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
10. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.
Skubitz KM; Pambuccian S; Manivel JC; Skubitz AP
J Transl Med; 2008 May; 6():23. PubMed ID: 18460215
[TBL] [Abstract][Full Text] [Related]
11. Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
Asanuma K; Nakamura T; Hayashi A; Okamoto T; Iino T; Asanuma Y; Hagi T; Kita K; Nakamura K; Sudo A
Sci Rep; 2020 Jun; 10(1):9077. PubMed ID: 32493964
[TBL] [Abstract][Full Text] [Related]
12. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma.
Nakayama R; Nemoto T; Takahashi H; Ohta T; Kawai A; Seki K; Yoshida T; Toyama Y; Ichikawa H; Hasegawa T
Mod Pathol; 2007 Jul; 20(7):749-59. PubMed ID: 17464315
[TBL] [Abstract][Full Text] [Related]
15. Histological grading and MIB-1 labeling index of soft-tissue sarcomas.
Hasegawa T
Pathol Int; 2007 Mar; 57(3):121-5. PubMed ID: 17295643
[TBL] [Abstract][Full Text] [Related]
16. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma.
Tsagozis P; Augsten M; Zhang Y; Li T; Hesla A; Bergh J; Haglund F; Tobin NP; Ehnman M
Cancer Immunol Immunother; 2019 Jun; 68(6):927-936. PubMed ID: 30879106
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow involvement in adult soft tissue sarcomas.
Bramwell VH; Littley MB; Chang J; Crowther D
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1099-106. PubMed ID: 6297916
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of soft tissue sarcoma proliferation.
Pollock RE
Semin Surg Oncol; 1994; 10(5):315-22. PubMed ID: 7997725
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in the genomics of soft tissue sarcomas.
Conley AP; Trent J; Zhang W
Curr Opin Oncol; 2008 Jul; 20(4):395-9. PubMed ID: 18525334
[TBL] [Abstract][Full Text] [Related]
20. DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas.
Weidema ME; van de Geer E; Koelsche C; Desar IME; Kemmeren P; Hillebrandt-Roeffen MHS; Ho VKY; van der Graaf WTA; Versleijen-Jonkers YMH; von Deimling A; Flucke UE;
Clin Cancer Res; 2020 Jan; 26(1):93-100. PubMed ID: 31562204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
